$12.65
-0.35[-2.69%]
Last update: 10:32AM Get Real Time Here
Cidara Therapeutics
(NASDAQ:CDTX)Cidara Therapeutics Stock (NASDAQ:CDTX), Analyst Ratings, Price Targets, Predictions
Cidara Therapeutics Inc has a consensus price target of $13.17, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from WBB Securities, Needham, and Cantor Fitzgerald on April 25, 2024. With an average price target of $21.67 between WBB Securities, Needham, and Cantor Fitzgerald, there's an implied 71.28% upside for Cidara Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
WBB Securities
Needham
Cantor Fitzgerald
HC Wainwright & Co.
Aegis Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cidara Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | 216.21% | WBB Securities | Stephen Brozak | → $40 | Maintains | Strong Buy | Get Alert |
| 04/25/2024 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | 97.63% | Needham | Joseph Stringer | $3 → $25 | Maintains | Buy | Get Alert |
| 04/25/2024 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 04/23/2024 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 04/08/2024 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | $120 → $120 | Maintains | Buy | Get Alert |
| 12/07/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -76.28% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -76.28% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/07/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -76.28% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | → Buy | Get Alert |
| 08/01/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -60.47% | Cantor Fitzgerald | Louise Chen | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -52.57% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -76.28% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | CDTX | Buy Now | Cidara Therapeutics | $12.65 | -76.28% | Needham | Joseph Stringer | → $60 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Cidara Therapeutics (CDTX)?
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by WBB Securities on April 25, 2024. The analyst firm set a price target for $40.00 expecting CDTX to rise to within 12 months (a possible 216.21% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by WBB Securities, and Cidara Therapeutics maintained their strong buy rating.
When was the last upgrade for Cidara Therapeutics (CDTX)?
The last upgrade for Cidara Therapeutics Inc happened on September 22, 2021 when WBB Securities raised their price target to N/A. WBB Securities previously had a buy for Cidara Therapeutics Inc.
When was the last downgrade for Cidara Therapeutics (CDTX)?
There is no last downgrade for Cidara Therapeutics.
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a maintained with a price target of $0.00 to $40.00. The current price Cidara Therapeutics (CDTX) is trading at is $12.65, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.